Journal
FUTURE ONCOLOGY
Volume 7, Issue 12, Pages 1385-1397Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FON.11.122
Keywords
biomarkers; circulating free DNA; circulating tumor cells; colorectal cancer; esophageal cancer; gastric cancer; prognostic
Categories
Funding
- Spanish Society of Medical Oncology (SEOM)
- European Society for Medical Oncology (ESMO)
Ask authors/readers for more resources
Circulating tumor cells (CTCs) and circulating free DNA (cfDNA) have been studied as promising prognostic and predictive tumor-derived biomarkers in the bloodstream of patients with gastrointestinal malignancies because they may be an alternative noninvasive tool to tumor tissue biopsies. Quantification and molecular characterization of CTCs and cfDNA may provide additional insights into cancer biology, potentially revealing novel targets to individualize cancer care. The present article aims to review the biology and current methods to assess CTCs and cfDNA, and the efforts to establish both tumor-derived biomarkers as prognostic and predictive factors in esophageal, gastric and colorectal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available